Angiosarcoma

被引：737

作者：

Young, Robin J. ^{[1
]}

Brown, Nicola J.

Reed, Malcolm W.

Hughes, David ^{[3
]}

Wall, Penella J. ^{[2
]}

机构：

[1] Sch Med & Biomed Sci, Acad Unit Surg Oncol, Dept Oncol, Sheffield S10 2RX, S Yorkshire, England

[2] Univ Sheffield, Sch Med & Biomed Sci, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England

[3] Sheffield Teaching Hosp NHS Fdn Trust, Dept Histopathol, Sheffield, S Yorkshire, England

来源：

LANCET ONCOLOGY | 2010年 / 11卷 / 10期

关键词：

SOFT-TISSUE SARCOMAS; PHASE-II TRIAL; CUTANEOUS ANGIOSARCOMA; HEPATIC ANGIOSARCOMA; TREATMENT OUTCOMES; PROGNOSTIC-FACTORS; CLINICAL-FEATURES; BREAST-CANCER; PACLITAXEL; OVEREXPRESSION;

D O I：

10.1016/S1470-2045(10)70023-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiosarcomas are rare soft-tissue sarcomas of endothelial cell origin that have a poor prognosis. They can arise anywhere in the body, most commonly presenting as cutaneous disease in elderly white men, involving the head and neck and particularly the scalp. They can be caused by therapeutic radiation or chronic lymphoedema and hence secondary breast angiosarcomas are an important subgroup. Recent work has sought to establish the molecular biology of angiosarcomas and identify specific targets for treatment. Interest is now focused on trials of vascular-targeted drugs, which are showing promise in the control of angiosarcomas. In this review we discuss angiosarcoma and its current management, with a focus on clinical trials investigating the treatment of advanced disease.

引用

页码：983 / 991

页数：9

共 88 条

[1] Treatment and outcome of 82 patients with angiosarcoma [J].